Care should reach everyone who wants it.
Elva was built on a single conviction: that access to the best science in metabolic health, longevity and weight management should not be a function of geography or income. We are making that true, worldwide.
We were not trying to disrupt healthcare. We were trying to make it fair.
The GLP-1 revolution changed the conversation around metabolic health permanently. Peer-reviewed study after peer-reviewed study showed outcomes that no previous intervention had reliably delivered at scale. Not for a subset of patients. Not for a year. Sustained, measurable, meaningful change in body weight, cardiovascular risk, and quality of life.
The active compounds at the centre of that revolution are peptides. They can be compounded to pharmaceutical grade by licensed facilities at a fraction of the cost of the branded versions. The purity is the same. The molecule is the same. The clinical evidence behind it is the same.
What was different was who could get it. We built Elva to change that.
“The science was there. The access was not. That is the gap Elva exists to close.”
We spent two years building the supply chain, the quality framework, and the clinical infrastructure to bring pharmaceutical-grade compounded Semaglutide, Tirzepatide, Retatrutide and NAD+ compounds to anyone who wants them, without the cost barriers that have historically made this kind of care exclusive.
The science of living longer, better.
GLP-1 agonists were the first chapter. The broader story of what Elva is building towards is healthspan, not just years of life but years of health, energy and function.
NAD+ (nicotinamide adenine dinucleotide) is the co-enzyme at the centre of cellular energy production. Levels decline significantly with age, by some estimates, by half between the ages of 40 and 60. Precursors like NMN and NR have demonstrated in clinical and pre-clinical research the ability to raise NAD+ levels and support mitochondrial function, DNA repair and metabolic efficiency.
Peptide protocols including BPC-157, TB-500, CJC-1295 and others are being studied for their roles in tissue repair, recovery, growth hormone modulation and metabolic regulation. The direction is consistent: precision compounds that work with your body's own systems to extend and improve function.
Elva exists at the intersection of what the science currently supports and what people can actually access. As the evidence base grows, so does what we offer. Our commitment is to the compound with the strongest data, at the most accessible price, with the most transparent quality framework we can build.
What we stand for.
Access without compromise.
The same pharmaceutical-grade compounds. The same independent batch testing. The same clinical outcomes. At a price that does not require you to choose between your health and everything else.
Longevity is the goal.
Weight management is one outcome. The deeper ambition is adding healthy years. NAD+ precursors, metabolic compounds, peptide protocols. We work across the full spectrum of what science currently offers for healthspan.
Honest, always.
We supply compounded preparations. We say that clearly. We are not a pharmacy and we do not pretend to be. Every batch is independently tested. Every certificate of analysis is available on request.
Pharmaceutical-grade compounds
HPLC purity tested to 99%+. EU GMP Annex 1 manufacturing. Independent third-party batch verification on every order.
Compounded, not branded
Same active molecule. A fraction of the cost. The difference is the supply chain. We built ours to pass savings directly to you.
Science-led, always evolving
GLP-1 agonists, NAD+ precursors, longevity peptides. As the evidence base expands, so does what we offer.
Global from day one
Compounding partners across the US, UK and EU. Serving customers worldwide. The belief that care should reach everyone applies everywhere.
Start where the science is strongest.
Take the two-minute eligibility quiz and see what is available to you. No waiting rooms. No gatekeeping. Care that actually reaches you.